ArticleEuropean journal of pain (London, England)2025
The mRNA Translation Inhibitor Vioprolide A Prevents Inflammatory Pain-Like Behaviour With Limited Action on Already Established Pain-Like Behaviour in Mice.
Article in European journal of pain (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-cell multi-omics sequencing reveals cell-specific transcriptomic and chromatin accessibility profiles in gut microbiome metabolite butyrate-produced pain modulation.International journal of oral science · 2026Article
- The mRNA Translation Inhibitor Vioprolide A Prevents Inflammatory Pain-Like Behaviour With Limited Action on Already Established Pain-Like Behaviour in Mice.European journal of pain (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAccumulating evidence indicates that pharmacological inhibition of the translational machinery is a therapeutic strategy for various diseases. However, whether inhibitors of mRNA translation might be suitable for pain therapy remains poorly understood. Here, we tested the potential analgesic effects of the natural product vioprolide A, which targets nucleolar protein 14 (NOP14) that is essential for ribosome biogenesis, in mouse models of pain.
methodsWe assessed the antinociceptive effects of vioprolide A in C57BL/6 mice using four different models: zymosan-induced peritonitis, zymosan-induced paw inflammation, complete Freund's adjuvant-induced paw inflammation and spared nerve injury. Plasma and brain levels of vioprolide A were determined in a pharmacokinetic study. Immunostaining and western blot experiments were performed to investigate the distribution and expression of NOP14 in dorsal root ganglia.
resultsPretreatment with vioprolide A alleviated the visceral inflammatory hypersensitivity during zymosan-induced peritonitis, and it attenuated the somatic inflammatory hypersensitivity during zymosan-induced paw inflammation in a dose-dependent manner. However, treatment with vioprolide A did not affect established hypersensitivities. Pharmacokinetic measurements revealed that vioprolide A was not brain-penetrant and exhibited a short plasma half-life, which however seems to be sufficient to exert long-lasting antinociceptive effects. Tissue stainings revealed that NOP14 is expressed in a population of sensory neurons.
conclusionsOur findings imply that vioprolide A may alleviate inflammatory nociceptive behaviours, but highlight that these effects may be limited to specific types of pain and treatment strategies. SIGNIFICANCE STATEMENT: The inhibitor of mRNA translation, vioprolide A, produced robust antinociception in distinct murine models of pain. This study provides evidence supporting further investigation of mRNA translation inhibitors, which attenuate pain by a novel mechanism of action that is not shared by established analgesics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.